Kinetics of antipyrine and sulfamethazine in patients recovered from dihydralazine-hepatitis.
Pharmacokinetic studies with sulfamethazine (500 mg) and antipyrine (15 mg/kg) were performed in 27 hypertonic patients (16 females, 11 males, 37-78 years) who had recovered from a dihydralazine-induced hepatitis, and 21 patients with essential hypertension (13 females, 8 males, 18-74 years) treated with antihypertonics excluding dihydralazine. 20 patients of the hepatitis group (74%) and 12 patients of the control group (57%) were slow acetylators. With regard to the pharmacokinetic parameters no differences were found in both slow and rapid acetylators between the sulfamethazine group and the antipyrine group.
Siegmund
W
W
Department of Clinical Pharmacology, University of Greifswald, GDR.
Franke
G
G
Baumgarten
R
R
Fengler
J D
JD
Krüger
R
R
Reichardt
R
R
D000107:Acetylation; D000328:Adult; D000368:Aged; D000983:Antipyrine / Q000493:pharmacokinetics*; D056486:Chemical and Drug Induced Liver Injury / Q000378:metabolism*; D004078:Dihydralazine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D013418:Sulfamethazine / Q000493:pharmacokinetics*
D006830:Hydralazine; D013418:Sulfamethazine; D004078:Dihydralazine; D000983:Antipyrine